Jonuleit; Helmut

Patent Applications and Registrations

Patent applications and USPTO patent grants for Jonuleit; Helmut.The latest application filed is for "screening method for the identification of agents capable of activating cd4+cd25+ regulatory t-cells through interactions with the hiv-1 gp120 binding site on cd4".

Company Profile

2.15.11

Jonuleit; Helmut - Russelsheim DE
Jonuleit; Helmut - Ginsheim-Gustavsburg DE
Jonuleit; Helmut - DE DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
In-vitro methods for the detection of autoimmune diseases or conditions Grant 11,447,825 - Trinschek , et al. September 20, 2	2022-09-20
Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4 App 20200316167 - Schneider; Franz-Josef ; et al.	2020-10-08
Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4 Grant 10,729,742 - Schneider , et al.	2020-08-04
In-vitro methods for the detection of autoimmune diseases or conditions App 20180216186 - Trinschek; Bettina ; et al.	2018-08-02
Humanized anti-CD4 antibody with immunosuppressive properties Grant 9,758,581 - Wijdenes , et al. September 12, 2	2017-09-12
Screening Method For The Identification Of Agents Capable Of Activating Cd4+cd25+ Regulatory T-cells Through Interactions With The Hiv-1 Gp120 Binding Site On Cd4 App 20170014474 - Schneider; Franz-Josef ; et al.	2017-01-19
Humanized Anti-CD4 Antibody With Immunosuppressive Properties App 20140220008 - Wijdenes; John ; et al.	2014-08-07
Screening Method for the Identification of Agents Capable of Activating CD4+CD25+ Regulatory T-Cells Through Interactions with the HIV-1 GP120 Binding Site on CD4 App 20140093509 - Schneider; Franz-Josef ; et al.	2014-04-03
Method for screening for an anti-CD4 antibody suitable for use in immunotherapy Grant 8,685,651 - Wijdenes , et al. April 1, 2	2014-04-01
Humanized anti-CD4 antibody with immunosuppressive properties Grant 8,673,304 - Wijdenes , et al. March 18, 2	2014-03-18
Humanized anti-CD4 antibody with immunosuppressive properties Grant 8,586,715 - Wijdenes , et al. November 19, 2	2013-11-19
Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4 Grant 8,557,533 - Schneider , et al. October 15, 2	2013-10-15
Humanized anti-CD4 antibody with immunosuppressive properties Grant 8,440,806 - Wijdenes , et al. May 14, 2	2013-05-14
Humanized Anti-cd4 Antibody With Immunosuppressive Properties App 20100291676 - WIJDENES; JOHN ; et al.	2010-11-18
Specific Activation Of A Regulatory T Cell And Its Use For Treatment Of Asthma, Allergic Disease, Autoimmune Disease, Graft Rejection And For Tolerance Induction App 20100074904 - Schneider; Franz-Josef ; et al.	2010-03-25
Humanized Anti-cd4 Antibody With Immunosuppressive Properties App 20090208497 - Wijdenes; John ; et al.	2009-08-20
Humanized Anti-cd4 Antibody With Immunosuppressive Properties App 20090208496 - Wijdenes; John ; et al.	2009-08-20
Humanized Anti-cd4 Antibody With Immunosuppressive Properties App 20090104190 - Wijdenes; John ; et al.	2009-04-23
Humanized anti-CD4 antibody with immunosuppressive properties Grant 7,452,981 - Wijdenes , et al. November 18, 2	2008-11-18
Regulatory T-Cells Containing Galectins for the Therapy and Diagnosis of Diseases App 20080118515 - Lutter; Petra ; et al.	2008-05-22

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.